OMGA

Analyst Sentiment

Wall St. Consensus
Buy
7 analysts·Limited coverage
71
Score
6 Buy (86%)1 Hold (14%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
686%
Hold
114%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$7.00
+4808.8%
Consensus
$9.00
+6211.4%
Bull
$11.00
+7613.9%
12-Month Target Range7 analysts
$7.00$9.00$11.00
Current $0.14Consensus
Current Price
$0.14
Upside to Consensus
$8.86

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+151.17%
EPS
FY2028
Rev-36.86%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028E
Revenue Avg$7M$17M$10M
Low$7M$17M$10M
High$7M$17M$10M
EBITDA Avg$-1M$-3M$-2M
Low$-1M$-3M$-2M
High$-1M$-3M$-2M
EBIT Avg$-1M$-3M$-2M
Low$-1M$-3M$-2M
High$-1M$-3M$-2M
Net Income Avg$-24M$-15M$-6M
Low$-24M$-15M$-6M
High$-24M$-15M$-6M
EPS Avg$-0.44$-0.28$-0.12
Low$-0.44$-0.28$-0.12
High$-0.44$-0.28$-0.12
Analysts (Rev / EPS)1 / 11 / 11 / 1

Earnings Surprises

Recent Analyst Actions

Apr 3, 2024Piper Sandler
Omega Therapeutics (OMGA) PT Lowered to $9 at Piper Sandler
Target:$9.00
+199.0%from $3.01
Apr 1, 2024Loop Capital Markets
Omega Therapeutics (OMGA) PT Lowered to $7 at Chardan Capital Markets
Target:$7.00
+91.8%from $3.65
Dec 8, 2022H.C. Wainwright
HC Wainwright & Co. Initiates Coverage On Omega Therapeutics with Buy Rating, Announces Price Target of $11
Target:$11.00
+74.6%from $6.30
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.